Originally published as JCO Early Release 10.1200/JCO.2008.21.1060 on October 13 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Google Scholar Articles by Harousseau, J.-L. Articles by Moreau, P. PubMed PubMed Citation Articles by Harousseau, J.-L. Articles by Moreau, P. Social Bookmarking                            What's this?

Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials

From the Centre René Gauducheau Nantes; Centre Hospitalier Universitaire (CHU) Nantes; CHU Bordeaux; CHU Toulouse; CHU Rennes; CHU Grenoble; CHU Besançon; CHU Nancy; CHU Poitiers; CHU Lyon; CHU Lille; Institut Curie; CHU St Antoine, Paris, France; CHU Valais, Switzerland; and the Université de Louvain, Belgium.

Corresponding author: Jean-Luc Harousseau, MD, Centre René Gauducheau Bd Jacques Monod 44850 St Herblain, Nantes, France; e-mail: jl-harousseau{at}nantes.fnclcc.fr.

Purpose The prognostic impact of complete response (CR) achievement in multiple myeloma (MM) has been shown mostly in the context of autologous stem-cell transplantation. Other levels of response have been defined because, even with high-dose therapy, CR is a relatively rare event. The purpose of this study was to analyze the prognostic impact of very good partial response (VGPR) in patients treated with high-dose therapy.

Patients and Methods All patients were included in the Intergroupe Francophone du Myelome 99-02 and 99-04 trials and treated with vincristine, doxorubicin, and dexamethasone (VAD) induction therapy followed by double autologous stem-cell transplantation (ASCT). Best post-ASCT response assessment was available for 802 patients.

Results With a median follow-up of 67 months, median event-free survival (EFS) and 5-year EFS were 42 months and 34%, respectively, for 405 patients who achieved at least VGPR after ASCT versus 32 months and 26% in 288 patients who achieved only partial remission (P = .005). Five-year overall survival (OS) was significantly superior in patients achieving at least VGPR (74% v 61% P = .0017). In multivariate analysis, achievement of less than VGPR was an independent factor predicting shorter EFS and OS. Response to VAD had no impact on EFS and OS. The impact of VGPR achievement on EFS and OS was significant in patients with International Staging System stages 2 to 3 and for patients with poor-risk cytogenetics t(4;14) or del(17p).

Conclusion In the context of ASCT, achievement of at least VGPR is a simple prognostic factor that has importance in intermediate and high-risk MM and can be informative in more patients than CR.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?